REFERENCES
1. World Health Organization. Obesity and overweight Geneva; 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [Last accessed on 30 Oct 2026].
2. Moschonis G, Trakman GL. Overweight and obesity: the interplay of eating habits and physical activity. Nutrients 2023;15:2896.
3. Ng M, Gakidou E, Lo J, et al. Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 2025;405:813-38.
4. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 2025;13:221-62.
5. Thomas DM, Bredlau C, Bosy-Westphal A, et al. Relationships between body roundness with body fat and visceral adipose tissue emerging from a new geometrical model. Obesity 2013;21:2264-71.
6. Wang CL, Hsu CY, Chu WM, Lin CY. Body roundness index outperforms body mass index in predicting 10-year atherosclerotic cardiovascular disease risk: evidence from a health screening cohort in Taiwan. Prev Med Rep 2025;60:103314.
7. Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017;377:13-27.
8. Valenzuela PL, Carrera-Bastos P, Castillo-García A, Lieberman DE, Santos-Lozano A, Lucia A. Obesity and the risk of cardiometabolic diseases. Nat Rev Cardiol 2023;20:475-94.
9. Di Angelantonio E, Bhupathiraju SN, Wormser D, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388:776-86.
10. Kim MS, Kim WJ, Khera AV, et al. Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and mendelian randomization studies. Eur Heart J 2021;42:3388-403.
11. Larsson SC, Bäck M, Rees JMB, Mason AM, Burgess S. Body mass index and body composition in relation to 14 cardiovascular conditions in UK biobank: a mendelian randomization study. Eur Heart J 2019;41:221-6.
12. Chen Y, Yu W, Lv J, et al. Early adulthood BMI and cardiovascular disease: a prospective cohort study from the China kadoorie biobank. Lancet Public Health 2024;9:e1005-13.
13. Jia X, Hu C, Xu Y, et al. Revisiting obesity thresholds for cardiovascular disease and mortality risk in Chinese adults: age- and gender-specific insights. Cell Rep Med 2025;6:102309.
14. Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. Lancet 2013;383:970-83.
15. Mongraw-Chaffin ML, Peters SAE, Huxley RR, Woodward M. The sex-specific association between BMI and coronary heart disease: a systematic review and meta-analysis of 95 cohorts with 1·2 million participants. Lancet Diabetes Endocrinol 2015;3:437-49.
16. Flint AJ, Rexrode KM, Hu FB, et al. Body mass index, waist circumference, and risk of coronary heart disease: A prospective study among men and women. Obes Res Clin Pract 2010;4:e171-81.
17. Sun M, Shi Y, Li N, et al. The global burden of cardiovascular diseases attributable to high body mass index, 1990-2023. Front Cardiovasc Med 2026;13:1689708.
18. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008;117:93-102.
19. Lindström S, Germain M, Crous-Bou M, et al. Assessing the causal relationship between obesity and venous thromboembolism through a mendelian randomization study. Hum Genet 2017;136:897-902.
20. Borch KH, Brækkan SK, Mathiesen EB, et al. Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the tromsø study. J Thromb Haemost 2009;7:739-45.
21. Borch KH, Brækkan SK, Mathiesen EB, et al. Anthropometric measures of obesity and risk of venous thromboembolism: the Tromso study. Arterioscler Thromb Vasc Biol 2010;30:121-7.
22. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022;145:e895-1032.
23. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-726.
24. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-13.
25. Pandey A, LaMonte M, Klein L, et al. Relationship between physical activity, body mass index, and risk of heart failure. J Am Coll Cardiol 2017;69:1129-42.
26. Savji N, Meijers WC, Bartz TM, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Fail 2018;6:701-9.
27. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471-7.
28. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity-results of a meta-analysis. Am Heart J 2008;155:310-5.
29. Ma M, Zhi H, Yang S, Yu EYW, Wang L. Body mass index and the risk of atrial fibrillation: A mendelian randomization study. Nutrients 2022;14:1878.
30. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term andlong-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 2002;39:578-84.
31. Stokes A, Preston SH. Smoking and reverse causation create an obesity paradox in cardiovascular disease. Obesity 2015;23:2485-90.
32. Preston SH, Stokes A. Obesity paradox: conditioning on disease enhances biases in estimating the mortality risks of obesity. Epidemiology 2014;25:454-61.
33. Banack HR, Kaufman JS. The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. Prev Med 2014;62:96-102.
34. Wade KH, Carslake D, Sattar N, Davey Smith G, Timpson NJ. BMI and mortality in UK biobank: revised estimates using mendelian randomization. Obesity 2018;26:1796-806.
35. Banack HR, Kaufman JS. Does selection bias explain the obesity paradox among individuals with cardiovascular disease? Ann Epidemiol 2015;25:342-9.
36. Sperrin M, Candlish J, Badrick E, Renehan A, Buchan I. Collider bias is only a partial explanation for the obesity paradox. Epidemiology 2016;27:525-30.
38. Elagizi A, Kachur S, Lavie CJ, et al. An overview and update on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis 2018;61:142-50.
39. Butt JH, Petrie MC, Jhund PS, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur Heart J 2023;44:1136-53.
40. Hauner H. Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc 2005;64:163-9.
41. Scheja L, Heeren J. The endocrine function of adipose tissues in health and cardiometabolic disease. Nat Rev Endocrinol 2019;15:507-24.
42. Crewe C, An YA, Scherer PE. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. J Clin Invest 2017;127:74-82.
43. Rutkowski JM, Stern JH, Scherer PE. The cell biology of fat expansion. J Cell Biol 2015;208:501-12.
44. Hosogai N, Fukuhara A, Oshima K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007;56:901-11.
45. Ivan M, Kondo K, Yang H, et al. HIFα targeted for vhl-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-8.
47. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch 2007;455:479-92.
48. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev 2013;93:1-21.
49. Grosfeld A, André J, Hauguel-de Mouzon S, Berra E, Pouysségur J, Guerre-Millo M. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J Biol Chem 2002;277:42953-7.
50. Jiang C, Kim JH, Li F, et al. Hypoxia-inducible factor 1α regulates a SOCS3-STAT3-Adiponectin signal transduction pathway in adipocytes. J Biol Chem 2013;288:3844-57.
51. Lee YS, Kim JW, Osborne O, et al. Increased adipocyte O2 consumption triggers HIF-1α, causing inflammation and insulin resistance in obesity. Cell 2014;157:1339-52.
52. Yu J, Shi L, Wang H, et al. Conditioned medium from hypoxia-treated adipocytes renders muscle cells insulin resistant. Eur J Cell Biol 2011;90:1000-15.
53. Liang X, Arullampalam P, Yang Z, Ming XF. Hypoxia enhances endothelial intercellular adhesion molecule 1 protein level through upregulation of arginase type II and mitochondrial oxidative stress. Front Physiol 2019;10:1003.
54. Fujisaka S, Usui I, Ikutani M, et al. Adipose tissue hypoxia induces inflammatory M1 polarity of macrophages in an HIF-1α-dependent and HIF-1α-independent manner in obese mice. Diabetologia 2013;56:1403-12.
55. Lumeng CN, Deyoung SM, Saltiel AR. Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am J Physiol Endocrinol Metab 2007;292:E166-74.
56. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and Macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005;25:2062-8.
57. Suganami T, Tanimoto-Koyama K, Nishida J, et al. Role of the toll-like receptor 4/NF-κB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and Macrophages. Arterioscler Thromb Vasc Biol 2007;27:84-91.
58. Gao D, Bing C. Macrophage‐induced expression and release of matrix metalloproteinase 1 and 3 by human preadipocytes is mediated by IL‐1β via activation of MAPK signaling. J Cell Physiol 2011;226:2869-80.
59. Luan D, Dadpey B, Zaid J, et al. Adipocyte-Secreted IL-6 sensitizes Macrophages to IL-4 signaling. Diabetes 2022;72:367-74.
60. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.
61. Huang S, Rutkowsky JM, Snodgrass RG, et al. Saturated fatty acids activate tlr-mediated proinflammatory signaling pathways. J Lipid Res 2012;53:2002-13.
62. Pal D, Dasgupta S, Kundu R, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 2012;18:1279-85.
63. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-25.
64. Shimizu I, Aprahamian T, Kikuchi R, et al. Vascular rarefaction mediates whitening of brown fat in obesity. J Clin Invest 2014;124:2099-112.
65. Rangel-Azevedo C, Santana-Oliveira DA, Miranda CS, Martins FF, Mandarim-de-Lacerda CA, Souza-Mello V. Progressive brown adipocyte dysfunction: whitening and impaired nonshivering thermogenesis as long-term obesity complications. J Nutr Biochem 2022;105:109002.
66. Ziqubu K, Dludla PV, Mthembu SXH, et al. An insight into brown/beige adipose tissue whitening, a metabolic complication of obesity with the multifactorial origin. Front Endocrinol 2023;14:1114767.
67. Kotzbeck P, Giordano A, Mondini E, et al. Brown adipose tissue whitening leads to brown adipocyte death and adipose tissue inflammation. J Lipid Res 2018;59:784-94.
68. Ouellet V, Labbé SM, Blondin DP, et al. Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humans. J Clin Invest 2012;122:545-52.
69. Bartelt A, Bruns OT, Reimer R, et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med 2011;17:200-5.
70. Ruan CC, Kong LR, Chen XH, et al. A2A receptor activation attenuates hypertensive cardiac remodeling via promoting brown adipose tissue-derived FGF21. Cell Metab 2018;28:476-89.e5.
71. Wang GX, Zhao XY, Meng ZX, et al. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis. Nat Med 2014;20:1436-43.
72. Pinckard KM, Shettigar VK, Wright KR, et al. A novel endocrine role for the bat-released lipokine 12,13-diHOME to mediate cardiac function. Circulation 2021;143:145-59.
73. Villarroya F, Cereijo R, Villarroya J, Giralt M. Brown adipose tissue as a secretory organ. Nat Rev Endocrinol 2016;13:26-35.
74. Alcalá M, Calderon-Dominguez M, Bustos E, et al. Increased inflammation, oxidative stress and mitochondrial respiration in brown adipose tissue from obese mice. Sci Rep 2017;7:16082.
75. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011;121:2111-7.
76. Sprenkle NT, Mills EL. Metabolite and nutrient regulation of macrophages in obesity and metabolic disease. Nat Rev Immunol 2026;26:613-26.
77. Schwartz EA, Zhang WY, Karnik SK, et al. Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. Arterioscler Thromb Vasc Biol 2010;30:802-8.
78. L'homme L, Esser N, Riva L, et al. Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages. J Lipid Res 2013;54:2998-3008.
79. Gao D, Pararasa C, Dunston CR, Bailey CJ, Griffiths HR. Palmitate promotes monocyte atherogenicity via de novo ceramide synthesis. Free Radic Biol Med 2012;53:796-806.
80. Getiye Y, Rice TA, Phillips BD, Carrillo DF, He G. Dysregulated lipolysis and lipophagy in lipid droplets of macrophages from high fat diet‐fed obese mice. J Cell Mol Med 2022;26:4825-36.
81. Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011;17:179-88.
82. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 2014;371:1131-41.
83. Britton KA, Fox CS. Ectopic fat depots and cardiovascular disease. Circulation 2011;124:e837-41.
84. Yamaguchi Y, Cavallero S, Patterson M, et al. Adipogenesis and epicardial adipose tissue: a novel fate of the epicardium induced by mesenchymal transformation and PPARγ activation. Proc Natl Acad Sci USA 2015;112:2070-5.
85. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022;19:593-606.
86. Liu B, Wang D, Xiong T, et al. Inhibition of notch signaling promotes the differentiation of epicardial progenitor cells into adipocytes. Stem Cells Int 2021;2021:1-2.
87. Tang QQ, Grønborg M, Huang H, et al. Sequential phosphorylation of CCAAT enhancer-binding protein β by MAPK and glycogen synthase kinase 3β is required for adipogenesis. Proc Natl Acad Sci USA 2005;102:9766-71.
88. Qureshi R, Kindo M, Arora H, Boulberdaa M, Steenman M, Nebigil CG. Prokineticin receptor-1-dependent paracrine and autocrine pathways control cardiac tcf21+ fibroblast progenitor cell transformation into adipocytes and vascular cells. Sci Rep 2017;7:12804.
89. Jaffer I, Riederer M, Shah P, et al. Expression of fat mobilizing genes in human epicardial adipose tissue. Atherosclerosis 2012;220:122-7.
90. Burgeiro A, Fuhrmann A, Cherian S, et al. Glucose uptake and lipid metabolism are impaired in epicardial adipose tissue from heart failure patients with or without diabetes. Am J Physiol Endocrinol Metab 2016;310:E550-64.
91. Ballasy NN, Jadli AS, Edalat P, et al. Potential role of epicardial adipose tissue in coronary artery endothelial cell dysfunction in type 2 diabetes. FASEB J 2021;35:e21878.
92. Leo S, Tremoli E, Ferroni L, Zavan B. Role of epicardial adipose tissue secretome on cardiovascular diseases. Biomedicines 2023;11:1653.
93. Parisi V, Rengo G, Perrone-Filardi P, et al. Increased epicardial adipose tissue volume correlates with cardiac sympathetic denervation in patients with heart failure. Circ Res 2016;118:1244-53.
94. Roubíček T, Dolinková M, Bláha J, et al. Increased angiotensinogen production in epicardial adipose tissue during cardiac surgery: possible role in a postoperative insulin resistance. Physiol Res 2008:911-7.
95. Shaihov-Teper O, Ram E, Ballan N, et al. Extracellular vesicles from epicardial fat facilitate atrial fibrillation. Circulation 2021;143:2475-93.
96. Ernault AC, de Winter R, Fabrizi B, et al. MicroRNAs in extracellular vesicles released from epicardial adipose tissue promote arrhythmogenic conduction slowing. Heart Rhythm O2 2023;4:805-14.
97. Blumensatt M, Fahlbusch P, Hilgers R, et al. Secretory products from epicardial adipose tissue from patients with type 2 diabetes impair mitochondrial β-oxidation in cardiomyocytes via activation of the cardiac renin-angiotensin system and induction of miR-208a. Basic Res Cardiol 2016;112:2.
98. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-129.
99. Ye RZ, Montastier É, Noll C, et al. Total postprandial hepatic nonesterified and dietary fatty acid uptake is increased and insufficiently curbed by adipose tissue fatty acid trapping in prediabetes with overweight. Diabetes 2022;71:1891-901.
100. Carreau AM, Noll C, Blondin DP, et al. Bariatric surgery rapidly decreases cardiac dietary fatty acid partitioning and hepatic insulin resistance through increased intra-abdominal adipose tissue storage and reduced spillover in type 2 diabetes. Diabetes 2020;69:567-77.
101. Zhang QJ, Holland WL, Wilson L, et al. Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. Diabetes 2012;61:1848-59.
102. Zhang L, Ussher JR, Oka T, Cadete VJJ, Wagg C, Lopaschuk GD. Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res 2010;89:148-56.
103. Laudette M, Sainte-Marie Y, Cousin G, et al. Cyclic AMP-binding protein Epac1 acts as a metabolic sensor to promote cardiomyocyte lipotoxicity. Cell Death Dis 2021;12:824.
104. Berezhnov AV, Fedotova EI, Nenov MN, Kasymov VA, Pimenov OY, Dynnik VV. Dissecting cellular mechanisms of long-chain acylcarnitines-driven cardiotoxicity: disturbance of calcium homeostasis, activation of Ca2+-Dependent phospholipases, and mitochondrial energetics collapse. Int J Mol Sci 2020;21:7461.
105. Aitken-Buck HM, Krause J, van Hout I, et al. Long-chain acylcarnitine 18:1 acutely increases human atrial myocardial contractility and arrhythmia susceptibility. Am J Physiol Heart Circ Physiol 2021;321:H162-74.
106. Trivedi PC, Bartlett JJ, Perez LJ, et al. Glucolipotoxicity diminishes cardiomyocyte TFEB and inhibits lysosomal autophagy during obesity and diabetes. Biochim Biophys Acta 2016;1861:1893-910.
107. Tong M, Mukai R, Mareedu S, et al. Distinct roles of DRP1 in conventional and alternative mitophagy in obesity cardiomyopathy. Circ Res 2023;133:6-21.
108. Huang JR, Zhang MH, Chen YJ, et al. Urolithin A ameliorates obesity-induced metabolic cardiomyopathy in mice via mitophagy activation. Acta Pharmacol Sin 2022;44:321-31.
109. Tong M, Saito T, Zhai P, et al. Mitophagy is essential for maintaining cardiac function during high fat diet-induced diabetic cardiomyopathy. Circ Res 2019;124:1360-71.
110. Ke J, Pan J, Lin H, et al. Targeting Rab7‐rilp mediated microlipophagy alleviates lipid toxicity in diabetic cardiomyopathy. Adv Sci 2024;11:2401676.
111. Hu Q, Zhang H, Gutiérrez Cortés N, et al. Increased Drp1 acetylation by lipid overload induces cardiomyocyte death and heart dysfunction. Circ Res 2020;126:456-70.
112. Yamamoto T, Endo J, Kataoka M, et al. Palmitate induces cardiomyocyte death via inositol requiring enzyme-1 (IRE1)-mediated signaling independent of x-box binding protein 1 (XBP1). Biochem Biophys Res Commun 2020;526:122-7.
113. Zou L, Li X, Wu N, Jia P, Liu C, Jia D. Palmitate induces myocardial lipotoxic injury via the endoplasmic reticulum stress-mediated apoptosis pathway. Mol Med Rep 2017;16:6934-9.
114. Stevens SA, Gonzalez Aguiar MK, Toro AL, et al. PERK/ATF4-dependent expression of the stress response protein REDD1 promotes proinflammatory cytokine expression in the heart of obese mice. Am J Physiol Endocrinol Metab 2023;324:E62-72.
115. Joseph LC, Subramanyam P, Radlicz C, et al. Mitochondrial oxidative stress during cardiac lipid overload causes intracellular calcium leak and arrhythmia. Heart Rhythm 2016;13:1699-706.
116. Sánchez G, Araneda F, Peña J, et al. High-Fat-Diet-Induced obesity produces spontaneous ventricular arrhythmias and increases the activity of ryanodine receptors in mice. Int J Mol Sci 2018;19:533.
117. Joseph LC, Reyes MV, Homan EA, et al. The mitochondrial calcium uniporter promotes arrhythmias caused by high-fat diet. Sci Rep 2021;11:17808.
118. Zhu M, Peng L, Huo S, et al. STAT3 signaling promotes cardiac injury by upregulating NCOA4-mediated ferritinophagy and ferroptosis in high-fat-diet fed mice. Free Radic Biol Med 2023;201:111-25.
119. Lee AS, Xi Y, Lai CH, et al. Human electronegative low-density lipoprotein modulates cardiac repolarization via LOX-1-mediated alteration of sarcolemmal ion channels. Sci Rep 2017;7:10889.
120. Campain J, Wakeham DJ, Dias K, et al. Distinct blood volume and left ventricular adaptation to severe obesity in middle-aged adults at risk for heart failure. Eur J Heart Fail 2025;27:2480-9.
121. Bhatti SN, Li JM. Nox2 dependent redox-regulation of akt and ERK1/2 to promote left ventricular hypertrophy in dietary obesity of mice. Biochem Biophys Res Commun 2020;528:506-13.
122. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-Kidney-Metabolic health: A presidential advisory from the American heart association. Circulation 2023;148:1606-35.
123. Basolo A, Salvetti G, Giannese D, et al. Obesity, hyperfiltration, and early kidney damage: a new formula for the estimation of creatinine clearance. J Clin Endocrinol Metab 2023;108:3280-6.
124. Sun Y, Ge X, Li X, et al. High-fat diet promotes renal injury by inducing oxidative stress and mitochondrial dysfunction. Cell Death Dis 2020;11:914.
125. Berger JH, Shi Y, Matsuura TR, et al. Two-hit mouse model of heart failure with preserved ejection fraction combining diet-induced obesity and renin-mediated hypertension. Sci Rep 2025;15:422.
126. Wang J, Li D, Zhang Y, Xing D, Lei Z, Jiao X. Angiotensin II type 1a receptor knockout ameliorates high-fat diet-induced cardiac dysfunction by regulating glucose and lipid metabolism. Acta Biochim Biophys Sin 2023;55:1380-92.
127. Ono H, Otaki Y, Watanabe T, et al. A novel mouse model of adenine-supplemented high-fat diet induced cardiovascular-kidney-metabolic syndrome. Hypertens Res 2026;49:2201-14.
128. Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American heart association. Circulation 2023;148:1636-64.
129. Zhao M, Wei H, Li C, et al. Gut microbiota production of trimethyl-5-aminovaleric acid reduces fatty acid oxidation and accelerates cardiac hypertrophy. Nat Commun 2022;13:1757.
130. Petrick HL, Ogilvie LM, Brunetta HS, et al. Dietary nitrate and corresponding gut microbiota prevent cardiac dysfunction in obese mice. Diabetes 2023;72:844-56.
131. Tilg H, Ianiro G, Gasbarrini A, Adolph TE. Adipokines: masterminds of metabolic inflammation. Nat Rev Immunol 2024;25:250-65.
132. Gough P, Myles IA. Tumor necrosis factor receptors: pleiotropic signaling complexes and their differential effects. Front Immunol 2020;11:585880.
133. Dondelinger Y, Aguileta MA, Goossens V, et al. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ 2013;20:1381-92.
134. Haas TL, Emmerich CH, Gerlach B, et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 2009;36:831-44.
135. Zegeye MM, Lindkvist M, Fälker K, et al. Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. Cell Commun Signal 2018;16:55.
136. Kunjathoor VV, Febbraio M, Podrez EA, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in Macrophages. J Biol Chem 2002;277:49982-8.
137. Dong N, Yang G, Liu Y, Wu K. Hydrogen sulfide inhibits early development of atherosclerosis by modulating macrophage uptake of oxidized lipoproteins. J Investig Med 2024;72:947-55.
138. Yang L, Yang JB, Chen J, et al. Enhancement of human ACAT1 gene expression to promote the macrophage-derived foam cell formation by dexamethasone. Cell Res 2004;14:315-23.
139. Spann NJ, Garmire LX, McDonald JG, et al. Regulated accumulation of desmosterol integrates Macrophage lipid metabolism and inflammatory responses. Cell 2012;151:138-52.
140. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol 2015;15:104-16.
141. Xiao W, Oldham WM, Priolo C, Pandey AK, Loscalzo J. Immunometabolic endothelial phenotypes: integrating inflammation and glucose metabolism. Circ Res 2021;129:9-29.
142. Martino N, Bossardi Ramos R, Chuy D, Tomaszek L, Adam AP. SOCS3 limits TNF and endotoxin-induced endothelial dysfunction by blocking a required autocrine interleukin-6 signal in human endothelial cells. Am J Physiol Cell Physiol 2022;323:C556-69.
143. Kim TK, Jeon S, Park S, et al. 2′-5′ oligoadenylate synthetase‑like 1 (OASL1) protects against atherosclerosis by maintaining endothelial nitric oxide synthase mRNA stability. Nat Commun 2022;13:6647.
144. Yu L, Xu L, Chu H, et al. Macrophage-to-endothelial cell crosstalk by the cholesterol metabolite 27HC promotes atherosclerosis in male mice. Nat Commun 2023;14:4101.
145. Su M, Zhao W, Jiang H, et al. Endothelial IGFBP6 suppresses vascular inflammation and atherosclerosis. Nat Cardiovasc Res 2025;4:145-62.
146. Kim YM, Krantz S, Jambusaria A, et al. Mitofusin-2 stabilizes adherens junctions and suppresses endothelial inflammation via modulation of β-catenin signaling. Nat Commun 2021;12:2736.
147. Richards M, Nwadozi E, Pal S, et al. Claudin5 protects the peripheral endothelial barrier in an organ and vessel-type-specific manner. Elife 2022;11:e78517.
148. Park M, Wu D, Park T, et al. APPL1 transgenic mice are protected from high-fat diet-induced cardiac dysfunction. Am J Physiol Endocrinol Metab 2013;305:E795-804.
149. Chen X, Ruiz-Velasco A, Zou Z, et al. PAK3 exacerbates cardiac lipotoxicity via SREBP1c in obesity cardiomyopathy. Diabetes 2024;73:1805-20.
150. Dalt L, Cabodevilla AG, Goldberg IJ, Norata GD. Cardiac lipid metabolism, mitochondrial function, and heart failure. Cardiovasc Res 2023;119:1905-14.
151. Meza U, Delgado‐Ramírez M, Romero‐Méndez C, Sánchez‐Armass S, Rodríguez‐Menchaca AA. Functional marriage in plasma membrane: critical cholesterol level-optimal protein activity. Br J Pharmacol 2020;177:2456-65.
152. Poulet C, Sanchez-Alonso J, Swiatlowska P, et al. Junctophilin-2 tethers t-tubules and recruits functional l-type calcium channels to lipid rafts in adult cardiomyocytes. Cardiovasc Res 2020;117:149-61.
153. Venkateshvaran A, Faxen UL, Hage C, et al. Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS‐HFpEF study. Eur J Heart Fail 2022;24:2251-60.
154. Crum Y, Hoendermis ES, van Veldhuisen DJ, et al. Epicardial adipose tissue and pericardial constraint in heart failure with preserved ejection fraction. ESC Heart Fail 2024;11:1698-706.
155. Tadokoro T, Li H, Gan P, et al. Ablation of PKCα phosphorylation by CRISPR-Cas9 base editing rescues heart failure. Circ Res 2026;138:e326738.
156. Alves-Figueiredo H, Silva-Platas C, Estrada M, et al. Mitochondrial Ca2+ uniporter-dependent energetic dysfunction drives hypertrophy in heart failure. JACC Basic Transl Sci 2024;9:496-518.
157. Chen H, Liu L, Li M, Zhu D, Tian G. Epicardial adipose tissue-derived leptin promotes myocardial injury in metabolic syndrome rats through PKC/NADPH oxidase/ROS pathway. J Am Heart Assoc 2023;12:e029415.
158. Xia YY, Shi Y, Li Z, et al. Involvement of pyroptosis pathway in epicardial adipose tissue - myocardium axis in experimental heart failure with preserved ejection fraction. Biochem Biophys Res Commun 2022;636:62-70.
159. Liberale L, Ministrini S, Carbone F, Camici GG, Montecucco F. Cytokines as therapeutic targets for cardio- and cerebrovascular diseases. Basic Res Cardiol 2021;116:23.
160. Andreadou I, Ghigo A, Nikolaou PE, et al. Immunometabolism in heart failure. Nat Rev Cardiol 2025;22:751-72.
161. Dobrev D, Heijman J, Hiram R, Li N, Nattel S. Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology. Nat Rev Cardiol 2022;20:145-67.
162. Tuleta I, Hanna A, Humeres C, et al. Fibroblast-specific TGF-β signaling mediates cardiac dysfunction, fibrosis, and hypertrophy in obese diabetic mice. Cardiovasc Res 2024;120:2047-63.
163. Packer M. Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? Eur Heart J 2025;47:12-21.
164. Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol 2023;81:1810-34.
165. Peikert A, Fontana M, Solomon SD, Thum T. Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment. Eur Heart J 2025;47:37-53.
166. Packer M. The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment. J Am Coll Cardiol 2025;86:1269-373.
167. Litwin SE, Komtebedde J, Seidler T, et al. Obesity in heart failure with preserved ejection fraction: insights from the REDUCE LAP-HF II trial. Eur J Heart Fail 2023;26:177-89.
168. Savarese G, Schiattarella GG, Lindberg F, et al. Heart failure and obesity: translational approaches and therapeutic perspectives. A scientific statement of the heart failure association of the ESC. Eur J Heart Fail 2025;27:1273-93.
169. Khan MS, Javaid SS, Petrie MC, Zieroth S, Anker SD, Butler J. Obesity and heart failure with reduced ejection fraction: a review. J Am Coll Cardiol 2026;87:3035-53.
170. Ho JE, Lyass A, Lee DS, et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail 2013;6:279-86.
171. van Essen BJ, Emmens JE, Tromp J, et al. Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years. Eur Heart J 2024;46:1528-36.
172. Rayner JJ, Abdesselam I, Pan J, Lewis AJM, Rider OJ. Obesity and heart failure: exploring the cardiometabolic axis. Cardiovasc Res 2025;121:1173-86.
173. Siddiqi HK, Vinayagamoorthy M, Gencer B, et al. Sex differences in atrial fibrillation risk: the VITAL rhythm study. JAMA Cardiol 2022;7:1027.
174. Tønnesen J, Pallisgaard J, Ruwald MH, et al. Short- and long-term risk of atrial fibrillation recurrence after first time ablation according to body mass index: a nationwide danish cohort study. Europace 2022;25:425-32.
175. Blum S, Aeschbacher S, Meyre P, et al. Incidence and predictors of atrial fibrillation progression. J Am Heart Assoc 2019;8:e012554.
176. Nalliah CJ, Bell JR, Raaijmakers AJA, et al. Epicardial adipose tissue accumulation confers atrial conduction abnormality. J Am Coll Cardiol 2020;76:1197-211.
177. Vickneson K, Gharaviri A, Vigneswaran V, et al. Peri-Atrial adipose tissue inflammation in atrial fibrillation: quantification of electrophysiological effects using electroanatomic mapping. JACC Clin Electrophysiol 2025;11:1968-79.
178. Ko WC, Hong CY, Hou SM, et al. Elevated expression of connective tissue growth factor in human atrial fibrillation and angiotensin II-treated cardiomyocytes. Circ J 2011;75:1592-600.
179. Fukui A, Takahashi N, Nakada C, et al. Role of leptin signaling in the pathogenesis of angiotensin II-mediated atrial fibrosis and fibrillation. Circ Arrhythm Electrophysiol 2013;6:402-9.
180. Singh R, Kaundal RK, Zhao B, Bouchareb R, Lebeche D. Resistin induces cardiac fibroblast-myofibroblast differentiation through JAK/STAT3 and JNK/c-jun signaling. Pharmacol Res 2021;167:105414.
181. Fujita K, Maeda N, Sonoda M, et al. Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-α. Arterioscler Thromb Vasc Biol 2008;28:863-70.
182. Abe I, Teshima Y, Kondo H, et al. Association of fibrotic remodeling and cytokines/chemokines content in epicardial adipose tissue with atrial myocardial fibrosis in patients with atrial fibrillation. Heart Rhythm 2018;15:1717-27.
183. Kawagishi H, Nakada T, Numaga-Tomita T, et al. Cytokine receptor gp130 promotes postnatal proliferation of cardiomyocytes required for the normal functional development of the heart. Am J Physiol Heart Circ Physiol 2022;323:H103-20.
184. Scott Jr L, Fender AC, Saljic A, et al. NLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmias. Cardiovasc Res 2021;117:1746-59.
185. Heijman J, Muna AP, Veleva T, et al. Atrial myocyte NLRP3/CaMKII nexus forms a substrate for postoperative atrial fibrillation. Circ Res 2020;127:1036-55.
186. Zeng L, Liu P, Rao F, et al. p300 upregulates ikur in atrial cardiomyocytes through activating NLRP3 inflammasome in hypertension. Chin Med J 2025;139:576-88.
187. Kamekura R, Nava P, Feng M, et al. Inflammation-induced desmoglein-2 ectodomain shedding compromises the mucosal barrier. Mol Biol Cell 2015;26:3165-77.
188. Chelko SP, Penna VR, Engel M, et al. NFĸB signaling drives myocardial injury via CCR2+ macrophages in a preclinical model of arrhythmogenic cardiomyopathy. J Clin Invest 2024;134:e172014.
189. Schinner C, Xu L, Franz H, et al. Defective desmosomal adhesion causes arrhythmogenic cardiomyopathy by involving an integrin-αVβ6/TGF-β signaling cascade. Circulation 2022;146:1610-26.
190. Emmerich SD, Fryar CD, Stierman B, Gu Q, Afful J, Ogden CL. Trends in obesity-related measures among US children, adolescents, and adults. JAMA 2025;333:1082.
191. Jeong SM, Lee DH, Rezende LFM, Giovannucci EL. Different correlation of body mass index with body fatness and obesity-related biomarker according to age, sex and race-ethnicity. Sci Rep 2023;13:3472.
192. Mouchti S, Orliacq J, Reeves G, Chen Z. Assessment of correlation between conventional anthropometric and imaging-derived measures of body fat composition: a systematic literature review and meta-analysis of observational studies. BMC Med Imaging 2023;23:127.
193. Coral DE, Smit F, Farzaneh A, et al. Subclassification of obesity for precision prediction of cardiometabolic diseases. Nat Med 2024;31:534-43.
194. Keating M, Saville GH, McCall L, Sainani KL, Ackerman KE. Dual-energy x-ray absorptiometry per cent fat z-score as a predictor of menstrual status in adolescent and young adult female athletes. Br J Sports Med 2026;60:362-9.
195. Ernst ME, Fravel MA, Woods RL, et al. Prevalence of obesity, excess central adiposity, and cardiovascular risk among older adults. JACC Adv 2025;4:102150.
196. Dardari ZA, Yao Z, Zhang J, et al. Risk reclassification beyond BMI by waist circumference and waist-to-hip ratio across 9 cardiovascular outcomes: results from the cross-cohort collaboration. J Am Coll Cardiol 2026;88:670-84.
197. Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0·5 could be a suitable global boundary value. Nutr Res Rev 2010;23:247-69.
198. Zhou B, Bennett JE, Wickham AP, et al. General and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7·5 million participants. Lancet 2024;404:851-63.
199. Diabetes Association Professional Practice Committee for Obesity. Screening, diagnosis, evaluation, and staging of obesity in adults: standards of care in overweight and obesity-2026. BMJ Open Diabetes Res Care 2026;13:e006247.
200. Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J 2007;28:850-6.
201. World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008. Available from: https://www.who.int/publications/i/item/9789241501491 [Last accessed on 30 Oct 2026].
202. Zhang X, Yang L, Xiao C, Li J, Hu T, Li L. Association between waist-to-hip ratio and risk of myocardial infarction: a systematic evaluation and meta-analysis. Front Cardiovasc Med 2024;11:1438817.
203. Feng Q, Bešević J, Conroy M, et al. Waist-to-height ratio and body fat percentage as risk factors for ischemic cardiovascular disease: a prospective cohort study from UK biobank. Am J Clin Nutr 2024;119:1386-96.
204. Yang M, Liu J, Shen Q, et al. Body roundness index trajectories and the incidence of cardiovascular disease: evidence from the China health and retirement longitudinal study. J Am Heart Assoc 2024;13:e034768.
205. Huang Y, Sulek K, Stinson SE, et al. Lipid profiling identifies modifiable signatures of cardiometabolic risk in children and adolescents with obesity. Nat Med 2024;31:294-305.
206. Jung E, Kong SY, Ro YS, Ryu HH, Shin SD. Serum cholesterol levels and risk of cardiovascular death: A systematic review and a dose-response meta-analysis of prospective cohort studies. Int J Environ Res Public Health 2022;19:8272.
207. Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 2016;355:i5953.
208. Kyrou I, Tsantarlioti O, Panagiotakos DB, et al. Adiponectin circulating levels and 10-year (2002-2012) cardiovascular disease incidence: the ATTICA study. Endocrine 2017;58:542-52.
209. Batsis JA, Sahakyan KR, Singh P, Bartels SJ, Somers VK, Lopez-Jimenez F. Leptin, adiposity, and mortality: results from the national health and nutrition examination survey III, 1988 to 1994. Mayo Clin Proc 2015;90:481-91.
210. Gounden V, Devaraj S, Jialal I. The role of the triglyceride-glucose index as a biomarker of cardio-metabolic syndromes. Lipids Health Dis 2024;23:416.
211. Ding X, Wang X, Wu J, Zhang M, Cui M. Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies. Cardiovasc Diabetol 2021;20:76.
212. Zhi YW, Chen RG, Zhao JW, Zhou SX, He ZJ. Association between atherogenic index of plasma and risk of incident major adverse cardiovascular events. Int Heart J 2024;65:39-46.
213. West HW, Siddique M, Williams MC, et al. Deep-learning for epicardial adipose tissue assessment with computed tomography: implications for cardiovascular risk prediction. JACC Cardiovasc Imaging 2023;16:800-16.
214. Kammerlander AA, Lyass A, Mahoney TF, et al. Sex differences in the associations of visceral adipose tissue and cardiometabolic and cardiovascular disease risk: the framingham heart study. J Am Heart Assoc 2021;10:e019968.
215. Britton KA, Massaro JM, Murabito JM, Kreger BE, Hoffmann U, Fox CS. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol 2013;62:921-5.
216. Mancio J, Azevedo D, Saraiva F, et al. Epicardial adipose tissue volume assessed by computed tomography and coronary artery disease: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging 2017;19:490-7.
217. Antonopoulos AS, Sanna F, Sabharwal N, et al. Detecting human coronary inflammation by imaging perivascular fat. Sci Transl Med 2017;9:eaal2658.
218. Wang Z, Lyu C, Yang D, et al. Pericoronary fat attenuation index and major adverse cardiovascular events: a systematic review and meta-analysis. Quant Imaging Med Surg 2026;16:439-439.
219. Marco A. Cardiac magnetic resonance and ventricular arrhythmias: an indissoluble liaison. JACC Cardiovasc Imaging 2023;16:1550-1.
220. Soghomonian A, Dutour A, Kachenoura N, et al. Is increased myocardial triglyceride content associated with early changes in left ventricular function? Front Endocrinol 2023;14:1181452.
221. Gupta S, Ge Y, Singh A, Gräni C, Kwong RY. Multimodality imaging assessment of myocardial fibrosis. JACC Cardiovasc Imaging 2021;14:2457-69.
222. Drazner MH, Bozkurt B, Cooper LT, et al. 2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2025;85:391-431.
223. Lertlaksameewilai P, Songsangjinda T, Kaolawanich Y, Yindeengam A, Krittayaphong R. Extracellular volume and left ventricular hypertrophy by cardiac magnetic resonance are independent predictors of cardiovascular outcome in obesity. Sci Rep 2022;12:18758.
224. Duca F, Mascherbauer K, Donà C, et al. Association of epicardial adipose tissue on magnetic resonance imaging with cardiovascular outcomes: quality over quantity? Obesity 2024;32:1670-9.
225. Sperry BW, Bateman TM, Akin EA, et al. Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM. J Nucl Med 2022:1-19.
226. Pahk K, Kim EJ, Lee YJ, Kim S, Seo HS. Characterization of glucose uptake metabolism in visceral fat by 18 F-FDG PET/CT reflects inflammatory status in metabolic syndrome. PLoS One 2020;15:e0228602.
227. Fernández-Friera L, Fuster V, López-Melgar B, et al. Vascular inflammation in subclinical atherosclerosis detected by hybrid PET/MRI. J Am Coll Cardiol 2019;73:1371-82.
228. Iwatsuka R, Matsue Y, Yonetsu T, et al. Arterial inflammation measured by 18F-FDG-PET-CT to predict coronary events in older subjects. Atherosclerosis 2018;268:49-54.
229. Schindler TH, Fearon WF, Pelletier-Galarneau M, et al. Myocardial perfusion PET for the detection and reporting of coronary microvascular dysfunction: a JACC: cardiovascular imaging expert panel statement. JACC Cardiovasc Imaging 2023;16:536-48.
230. Peterson LR, Soto PF, Herrero P, et al. Impact of gender on the myocardial metabolic response to obesity. JACC Cardiovasc Imaging 2008;1:424-33.
231. Commandeur F, Goeller M, Razipour A, et al. Fully automated CT quantification of epicardial adipose tissue by deep learning: a multicenter study. Radiol Artif Intell 2019;1:e190045.
232. Sahashi Y, Ieki H, Yuan V, et al. Artificial intelligence automation of echocardiographic measurements. J Am Coll Cardiol 2025;86:964-78.
233. Daudé P, Ancel P, Confort Gouny S, et al. Deep-Learning segmentation of epicardial adipose tissue using four-chamber cardiac magnetic resonance imaging. Diagnostics 2022;12:126.
234. Watanabe K, Wilmanski T, Diener C, et al. Multiomic signatures of body mass index identify heterogeneous health phenotypes and responses to a lifestyle intervention. Nat Med 2023;29:996-1008.
235. Luo Y, Zhang N, Yang J, et al. AI-based multiomics profiling reveals complementary omics contributions to personalized prediction of cardiovascular disease. Nat Commun 2026;17:2269.
236. Khera R, Oikonomou EK, Nadkarni GN, et al. Transforming cardiovascular care with artificial intelligence: from discovery to practice: JACC state-of-the-art review. J Am Coll Cardiol 2024;84:97-114.
237. Demircan K, Carrasco-Zanini J, Williamson A, et al. Data-driven prioritization of high-risk individuals for weight loss interventions. Nat Med 2026;32:2117-27.
238. Iqbal J, Wu HX, Wu YX, et al. MetsObesity: a novel classification system for predicting 15-year cardiovascular risk in the UK biobank population. J Adv Res 2026;88:947-57.
239. Pastika L, Sau A, Patlatzoglou K, et al. Artificial intelligence-enhanced electrocardiography derived body mass index as a predictor of future cardiometabolic disease. NPJ Digit Med 2024;7:167.
240. Bermingham KM, Linenberg I, Polidori L, et al. Effects of a personalized nutrition program on cardiometabolic health: a randomized controlled trial. Nat Med 2024;30:1888-97.
241. Abegaz TM, Frietze G. Machine learning algorithms for predicting glycemic control and weight loss outcomes in GLP-1 receptor agonist users. Front Artif Intell 2026;9:1861563.
242. Saux P, Bauvin P, Raverdy V, et al. Development and validation of an interpretable machine learning-based calculator for predicting 5-year weight trajectories after bariatric surgery: a multinational retrospective cohort SOPHIA study. Lancet Digit Health 2023;5:e692-702.
243. Panunzi S, Russo S, Pompa M, et al. Personalizing bariatric metabolic surgery: predictors of weight-loss success and risk of weight recurrence. Metabolism 2026;177:156495.
244. Petek BJ, Al-Alusi MA, Moulson N, et al. Consumer wearable health and fitness technology in cardiovascular medicine: JACC state-of-the-art review. J Am Coll Cardiol 2023;82:245-64.
245. Zhang T, Liu N, Xu J, et al. Flexible electronics for cardiovascular healthcare monitoring. Innovation 2023;4:100485.
246. Liu X, Zhang J, Liu L, Tang X, Gao P. A population-based recalibration method for updating survival neural networks models for cardiovascular risk prediction in united kingdom and China. J Clin Epidemiol 2025;185:111895.
247. Gulati G, Upshaw J, Wessler BS, et al. Generalizability of cardiovascular disease clinical prediction models: 158 independent external validations of 104 unique models. Circ Cardiovasc Qual Outcomes 2022;15:e008487.
248. Sau A, Pastika L, Sieliwonczyk E, et al. Artificial intelligence-enabled electrocardiogram for mortality and cardiovascular risk estimation: a model development and validation study. Lancet Digit Health 2024;6:e791-802.
249. van Dam PMEL, van Doorn WPTM, Sevenich L, et al. Machine learning for risk stratification in the emergency department (MARS-ED): a randomized controlled trial. Nat Commun 2025;17:242.
250. Khan SS, Greenland P, Hayman LL, et al. Criteria to assess the predictive and clinical utility of novel models, biomarkers, and tools for risk of cardiovascular disease: A scientific statement from the American heart association. Circulation 2026;153:e953-70.
251. Ying Z, Fan Y, Chen C, et al. Real-Time AI-assisted insulin titration system for glucose control in patients with type 2 diabetes: a randomized clinical trial. JAMA Netw Open 2025;8:e258910.
252. Gilbert O, Gulati M, Gluckman TJ, et al. 2025 Concise clinical guidance: an ACC expert consensus statement on medical weight management for optimization of cardiovascular health: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2025;86:536-55.
253. Busetto L, Dicker D, Frühbeck G, et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med 2024;30:2395-9.
254. Pagidipati NJ, Taub PR, Ostfeld RJ, Kirkpatrick CF. Dietary patterns to promote cardiometabolic health. Nat Rev Cardiol 2024;22:38-46.
255. Sankaralingam S, Abo Alrob O, Zhang L, et al. Lowering body weight in obese mice with diastolic heart failure improves cardiac insulin sensitivity and function: implications for the obesity paradox. Diabetes 2014;64:1643-57.
256. Ma C, Avenell A, Bolland M, et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ 2017;359:j4849.
257. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 2018;378:e34.
258. Tucker WJ, Fegers-Wustrow I, Halle M, Haykowsky MJ, Chung EH, Kovacic JC. Exercise for primary and secondary prevention of cardiovascular disease: JACC focus Seminar 1/4. J Am Coll Cardiol 2022;80:1091-106.
259. Hastings MH, Castro C, Freeman R, et al. Intrinsic and extrinsic contributors to the cardiac benefits of exercise. JACC Basic Transl Sci 2024;9:535-52.
260. Martinez MW, Kim JH, Shah AB, et al. Exercise-Induced cardiovascular adaptations and approach to exercise and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol 2021;78:1453-70.
261. Mitchell JH, Haskell W, Snell P, Van Camp SP. Task force 8: classification of sports. J Am Coll Cardiol 2005;45:1364-7.
262. Valenzuela PL, Ruilope LM, Santos-Lozano A, et al. Exercise benefits in cardiovascular diseases: from mechanisms to clinical implementation. Eur Heart J 2023;44:1874-89.
263. Slentz CA, Bateman LA, Willis LH, et al. Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT. Am J Physiol Endocrinol Metab 2011;301:E1033-9.
264. Mandal AK, Rana T, Shrestha S, et al. Effectiveness of aerobic exercise in reducing blood pressure among obese adults: systematic review and meta-analysis. J Hypertens 2025;43:1923-36.
265. Wakeham DJ, Pierce GL, Heffernan KS. Effect of acute resistance exercise and resistance exercise training on central pulsatile hemodynamics and large artery stiffness: part I. Pulse 2025;13:31-44.
266. Willis LH, Slentz CA, Bateman LA, et al. Effects of aerobic and/or resistance training on body mass and fat mass in overweight or obese adults. J Appl Physiol (1985) 2012;113:1831-7.
267. Braghieri HA, Silva GO, Farah BQ, et al. Effect of resistance exercise on ambulatory blood pressure: systematic review and meta-analysis. Int J Sports Med 2025;47:159-70.
268. K B S, Vaishali K, Kadavigere R, et al. Effects of high-intensity interval training versus moderate-intensity continuous training on vascular function among individuals with overweight and obesity-a systematic review. Int J Obes 2024;48:1517-33.
269. Poon ETC, Li HY, Little JP, Wong SHS, Ho RST. Efficacy of interval training in improving body composition and adiposity in apparently healthy adults: an umbrella review with meta-analysis. Sports Med 2024;54:2817-40.
270. Hansen D, Abreu A, Ambrosetti M, et al. Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: why and how: a position statement from the secondary prevention and rehabilitation section of the European association of preventive cardiology. Eur J Prev Cardiol 2021;29:230-45.
271. Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ 2025;197:E797-E809.
272. McGowan B, Ciudin A, Baker JL, et al. Framework for the pharmacological treatment of obesity and its complications from the European association for the study of obesity (EASO). Nat Med 2025;31:3229-32.
273. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74.
274. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.
275. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014;124:4473-88.
276. Beutler LR. GLP-1 physiology and pharmacology along the gut-brain axis. J Clin Invest 2026;136:e194744.
277. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22.
278. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22.
279. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989-1002.
280. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-32.
281. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-16.
282. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025;392:427-37.
283. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American society for metabolic and bariatric surgery (ASMBS) and international federation for the surgery of obesity and metabolic disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis 2022;18:1345-56.
284. Akalestou E, Miras AD, Rutter GA, le Roux CW. Mechanisms of weight loss after obesity surgery. Endocr Rev 2021;43:19-34.
285. Carlsson LMS, Sjöholm K, Jacobson P, et al. Life expectancy after bariatric surgery in the swedish obese subjects study. N Engl J Med 2020;383:1535-43.
286. Aminian A, Zajichek A, Arterburn DE, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA 2019;322:1271.
287. Bellicha A, Ciangura C, Poitou C, Portero P, Oppert JM. Effectiveness of exercise training after bariatric surgery-a systematic literature review and meta‐analysis. Obes Rev 2018;19:1544-56.
288. Marc-Hernández A, Ruiz-Tovar J, Aracil A, Guillén S, Moya-Ramón M. Effects of a high-intensity exercise program on weight regain and cardio-metabolic profile after 3 years of bariatric surgery: A randomized trial. Sci Rep 2020;10:3123.
289. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J 2024;45:3415-537.
290. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020;383:1838-47.
291. Schulz-Menger J, Collini V, Gröschel J, et al. 2025 ESC guidelines for the management of myocarditis and pericarditis. Eur Heart J 2025;46:3952-4041.
292. Klein AL, Imazio M, Cremer P, et al. Phase 3 trial of Interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med 2021;384:31-41.
293. Bhatt DL, Bays HE, Miller M, et al. The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nat Med 2023;29:1782-92.
294. Hundertmark MJ, Birkhoelzer SM, Portwood C, et al. IMPROVE-DiCE, a 2-part, open-label, phase 2a trial evaluating the safety and effectiveness of ninerafaxstat in patients with cardiometabolic syndromes. Circulation 2026;153:550-63.
295. Lewis GA, Dodd S, Clayton D, et al. Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat Med 2021;27:1477-82.
296. Ussher JR, Folmes CDL, Keung W, et al. Inhibition of serine palmitoyl transferase I reduces cardiac ceramide levels and increases glycolysis rates following diet-induced insulin resistance. PLoS One 2012;7:e37703.
297. Ruperez C, Madeo F, de Cabo R, Kroemer G, Abdellatif M. Obesity accelerates cardiovascular ageing. Eur Heart J 2025;46:2161-85.




